Dr. Edwin Posadas, MD

Dr. Posadas practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Posadas' NPI, 1720140270, was assigned on December 14, 2006. Dr. Posadas graduated from The Johns Hopkins University School of Medicine in 1998.

Dr. Posadas' primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Posadas' primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Posadas practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Posadas' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Posadas is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Posadas' licenses on file in 4 states: Illinois, California, Michigan and Maryland.

Dmand AI lists prostate cancer among the conditions Dr. Posadas treats.

CMS data shows 445 Medicare services from Dr. Posadas across 4 procedure codes in 2024, all of them office visits, for 137 Medicare patients. Medicare paid $42,059 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 137 Medicare patients who saw Dr. Posadas in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Posadas' median patient age at 74, with 8% women.

In 2024, Dr. Posadas wrote 166 Medicare Part D claims for 37 patients. 32% of them were for generic drugs. CMS names the drug for 102 of them, across 3 drugs with 11 or more claims each, at $786,670 in total drug cost. In 2023, CMS named 125 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Posadas for performance year 2024, reported as part of a group. Dr. Posadas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Posadas as offering telehealth.

Dmand AI links 98 papers to Dr. Posadas, published from 2005 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Prostatic Neoplasms, Antineoplastic Agents and Kidney Neoplasms. Dr. Posadas has published most often in Clin Cancer Res. Dr. Posadas' most frequent co-authors are Robert Alan Figlin, MD, Jun Gong and Vatche Garen Agopian, MD.

Dmand AI links Dr. Posadas to 11 clinical trials, 9 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 190 general payments to Dr. Posadas from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $125,972.

Dmand AI lists 14 awards for Dr. Posadas, most recently Castle Connoly Top Doctors in 2020.

Dr. Posadas graduated from The Johns Hopkins University School of Medicine in 1998. Dr. Posadas is a member of ACP, ASTRO, ASCO and AUA.

Dr. Posadas is in network with 13 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.